Zhitaoin Finance App learned that the stock price of Scholar Rock Holding Corp. (SRRK.USA) surged 335% in Monday's trading, this significant growth is due to its spinal muscular atrophy (SMA) candidate drug apitegromab successfully reaching the primary endpoint in phase III trials. This positive result demonstrates that apitegromab monoclonal antibody has a significant effect on improving patient motor function, especially at week 52, patients treated with apitegromab showed statistically significant improvements compared to the placebo group.

In the SAPPHIRE study, patients treated with apitegromab saw an average increase of over 3 points in the Hammersmith Functional Motor Scale Expanded (HFMSE) score at week 52, while only 12.5% of patients receiving placebo reached this level of improvement.

Furthermore, patients using apitegromab observed early improvements in motor function starting from week 8, and this improvement continued throughout the entire 52-week study period.

Given these positive data, Scholar Rock plans to submit a regulatory application for apitegromab to the Food and Drug Administration (FDA) in the USA and the European Medicines Agency (EMA) in the first quarter of 2025.

This move is expected to bring new treatment options for SMA patients and may further drive Scholar Rock's growth in the biopharmaceutical field.